Last €0.73 EUR
Change Today +0.01 / 1.39%
Volume 376.6K
MLM On Other Exchanges
Symbol
Exchange
BrsaItaliana
As of 6:10 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

molecular medicine spa (MLM) Snapshot

Open
€0.74
Previous Close
€0.72
Day High
€0.74
Day Low
€0.72
52 Week High
01/13/14 - €0.88
52 Week Low
04/26/13 - €0.40
Market Cap
168.8M
Average Volume 10 Days
1.8M
EPS TTM
€-0.08
Shares Outstanding
230.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MOLECULAR MEDICINE SPA (MLM)

Related News

No related news articles were found.

molecular medicine spa (MLM) Related Businessweek News

No Related Businessweek News Found

molecular medicine spa (MLM) Details

MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its product pipeline includes two novel anticancer therapeutics in clinical development stage that comprise TK, a cell-based therapy, which is in Phase III clinical trials enabling bone marrow transplants from partially compatible donors for high-risk leukaemia; and NGR-hTNF, a novel vascular targeting agent that is in Phase III clinical trials for malignant pleural mesothelioma. The company’s NGR-hTNF product candidate is also in Phase II clinical for seven different types of solid tumours, including colorectal, smallcell lung, non-small-cell lung, pleural mesothelioma, liver, and ovarian cancers, as well as soft tissue sarcomas. MolMed S.p.A. has strategic partnership with Takara Bio, Inc. for the development of its cell-based therapies in Asia; and collaboration agreement with Telethon Foundation for the development and manufacture of gene therapies for rare genetic diseases and lentiviral vectors, as well as an agreement with San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy. The company was founded in 1996 and is based in Milan, Italy.

Founded in 1996

molecular medicine spa (MLM) Top Compensated Officers

Founder, Chairman, Chairman of the Scientific...
Total Annual Compensation: €771.0K
General Manager of R&D & Operations and Execu...
Total Annual Compensation: €390.0K
Director of Investor Relations, General Manag...
Total Annual Compensation: €399.0K
Compensation as of Fiscal Year 2012.

molecular medicine spa (MLM) Key Developments

MolMed S.p.A., Annual General Meeting, Apr 08, 2014

MolMed S.p.A., Annual General Meeting, Apr 08, 2014., at 11:00 Central European Standard Time. Location: NH Hotel Milano 2, via Fratelli Cervi. Agenda: To consider approval of the financial statements for the fiscal year ended December 31, 2013; and to consider resolution on Section I of the report on remuneration, pursuant to article 123-tier of the Italian consolidated law on finance.

MolMed S.p.A., Special/Extraordinary Shareholders Meeting, Mar 03, 2014

MolMed S.p.A., Special/Extraordinary Shareholders Meeting, Mar 03, 2014.

MolMed S.p.A. Presents at 7th Annual European Life Sciences CEO Forum, Mar-05-2014 11:15 AM

MolMed S.p.A. Presents at 7th Annual European Life Sciences CEO Forum, Mar-05-2014 11:15 AM. Venue: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Switzerland.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MLM:IM €0.73 EUR +0.01

MLM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MLM.
View Industry Companies
 

Industry Analysis

MLM

Industry Average

Valuation MLM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.6x
Price/Book 16.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOLECULAR MEDICINE SPA, please visit www.molmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.